AGEN May 2024 10.000 call
| Previous close | 0.6100 |
| Open | 0.6000 |
| Bid | 0.4000 |
| Ask | 1.4000 |
| Strike | 10.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.6000 - 1.3900 |
| Contract range | N/A |
| Volume | |
| Open interest | 157 |
- Business Wire
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
LEXINGTON, Mass., May 16, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as the
Insider MonkeyAgenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript May 7, 2024 Agenus Inc. beats earnings expectations. Reported EPS is $-3.04104, expectations were $-3.1. AGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to […]
Simply Wall St.Agenus First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Agenus ( NASDAQ:AGEN ) First Quarter 2024 Results Key Financial Results Revenue: US$28.0m (up 22% from 1Q 2023). Net...
